JANUVIA 50MG

About

JANUVIA 50MG contains sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. This medication works by enhancing the body's natural ability to lower high blood glucose levels. It does this by increasing the levels of active incretin hormones (GLP-1 and GIP), which are released after a meal. These hormones stimulate insulin release from the pancreas and decrease glucagon secretion from the liver, both in a glucose-dependent manner, thereby improving glycemic control.

Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It offers a targeted approach to managing blood sugar without directly stimulating insulin secretion in a non-glucose-dependent manner, which contributes to its low risk of hypoglycemia when used as monotherapy. Its mechanism helps to normalize both fasting and post-meal glucose levels.

Uses

• Management of type 2 diabetes mellitus.
• As an adjunct to diet and exercise.
• To improve glycemic control in adults.
• Can be used as monotherapy or in combination with other antidiabetic agents.

Directions For Use

Take JANUVIA 50MG orally once daily, with or without food, as prescribed by your physician.

Benefits

• Effective reduction in HbA1c levels.
• Low risk of hypoglycemia when used alone.
• Generally weight-neutral.
• Improves both fasting and post-meal glucose levels.
• Well-tolerated with a favorable safety profile.
• Enhances natural incretin hormone activity.

Side Effects

• Nasopharyngitis
• Headache
• Upper respiratory tract infection
• Diarrhea
• Nausea
• Abdominal pain
• Joint pain
• Hypoglycemia (when combined with sulfonylurea/insulin)
• Pancreatitis (rare)
• Allergic reactions (rare)
• Bullous pemphigoid (rare)
• Kidney problems (rare)

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake should be avoided as it can affect blood sugar levels.
• Pregnancy - Generally not recommended during pregnancy. Consult your doctor to discuss potential risks and benefits.
• Breastfeeding - Not advised during breastfeeding as sitagliptin may pass into breast milk. Seek medical advice.
• Liver - No dose adjustment is typically required for mild to moderate liver impairment. Use with caution in severe hepatic dysfunction.
• Kidney - Dose adjustment is necessary based on kidney function (eGFR). Not recommended for patients with severe renal impairment or end-stage renal disease requiring dialysis.
• Lung - No specific contraindications related to lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.